Humana (HUM) is a Top-Ranked Momentum Stock: Should You Buy?

Humana (HUM) is highlighted as a noteworthy stock for investors, particularly those focused on momentum, despite its Zacks #3 (Hold) rank. The healthcare provider has seen its shares rise 15.5% over the past four weeks, supported by a 'B' Momentum Style Score and 'B' VGM Score. This positive trend is reinforced by 11 analysts revising their fiscal 2025 earnings estimates higher in the last 60 days, increasing the Zacks Consensus Estimate by $0.62 to $16.99 per share, signaling strong positive sentiment and earnings momentum for the company.

Analysis

Humana (HUM) is presenting a compelling case for momentum-focused investors, underpinned by both strong price action and positive revisions in analyst earnings estimates. Despite a neutral Zacks #3 (Hold) rank, the stock has surged 15.5% over the past four weeks, earning it a 'B' grade in the Zacks Momentum Style Score. This market momentum is fundamentally supported by a significant shift in analyst sentiment for fiscal 2025; over the last 60 days, 11 analysts have revised their earnings estimates upward, lifting the Zacks Consensus Estimate by $0.62 to $16.99 per share. This positive earnings outlook is further corroborated by the company's historical performance, which includes an average earnings surprise of +9.6%. The stock's 'B' rating for its composite VGM Score indicates a favorable blend of value, growth, and momentum characteristics, suggesting that the recent positive trend is not one-dimensional.

Key Decisions for Investors

• Momentum-oriented investors should consider HUM for their watchlist, as the 15.5% price increase in four weeks combined with a 'B' Momentum Score highlights a strong upward trend.
• Investors should note the positive fundamental shift indicated by 11 upward earnings revisions for fiscal 2025, which may precede a potential upgrade from its current Zacks #3 (Hold) rank.
• Given the divergence between the strong momentum indicators and the neutral 'Hold' rating, it is prudent to monitor whether the forward earnings momentum can be sustained to justify the recent price appreciation.